Featured Research

from universities, journals, and other organizations

Scientists make advance in cancer research

Date:
January 3, 2014
Source:
University of East Anglia
Summary:
A protein that has been at the center of cancer drug design for the last 20 years should not be overlooked according to new research.

A protein that has been at the center of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).

The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer.

But research published today in the American Heart Association's journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of tumors. Not least because the drugs targeting it cause minimal side effects compared to other drugs -- which can cause bleeding in the gut and high blood pressure.

tumors must recruit their own blood supply to grow beyond a very small size. The research team studied the cells that line blood vessels (endothelial cells) in mice, and in particular the role of a widely expressed protein called beta3-integrin.

Dr Stephen Robinson, from UEA's school of Biological Sciences, said: "This protein has been the focus of drug design over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment.

"The most advanced of these drugs, however, has recently failed a phase III clinical trial to treat an aggressive form of brain cancer. In line with other clinical work, patients respond to treatment for a short while but then their cancers escape the treatment.

"This research helps to explain why these very promising drugs aren't meeting with the success that was anticipated and it suggests a way forward -- how to make them work better.

"We have shown how tumors continue to grow despite treatment which should block blood vessel recruitment. They modulate how they are recruiting their blood vessels by using a different pathway from the one that is being targeted. We have identified some molecular changes in endothelial cells that occur with long-term inhibition of beta3-integrin that might help the cells escape the beta3-integrin blockade.

"Our research also shows that timing is critical when targeting the protein beta3-integrin.

"Importantly, these findings have re-established the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be re-focused to either develop new drugs to target beta3-integrin, or figure out how to more effectively use the drugs that already exist."


Story Source:

The above story is based on materials provided by University of East Anglia. Note: Materials may be edited for content and length.


Journal Reference:

  1. Stephen Robinson et al. Acute Depletion of Endothelial beta3-Integrin Transiently Inhibits Tumour Growth and Angiogenesis in Mice. Circulation Research, January 2014

Cite This Page:

University of East Anglia. "Scientists make advance in cancer research." ScienceDaily. ScienceDaily, 3 January 2014. <www.sciencedaily.com/releases/2014/01/140103085358.htm>.
University of East Anglia. (2014, January 3). Scientists make advance in cancer research. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2014/01/140103085358.htm
University of East Anglia. "Scientists make advance in cancer research." ScienceDaily. www.sciencedaily.com/releases/2014/01/140103085358.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins